Abcam, ab274899, Human PTPN2 knockout Jurkat cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
PTPN2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9; X = 10 bp deletion, 1 bp deletion, 2 bp insertion; Frameshift: 100%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:Jurkat,
Species or organism:Human,
Tissue:Blood,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 10 bp deletion, 1 bp deletion, 2 bp insertion; Frameshift: 100%,
Disease:Non-Hodgkin Lymphoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PTPN2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TCPTP or T-cell protein tyrosine phosphatase is an enzyme that functions mechanically by removing phosphate groups from tyrosine residues on its substrate proteins. This process helps regulate various signaling pathways within cells. Also known as PTPN2 TCPTP is a protein with a mass of approximately 48 kDa. Its expression occurs in many tissues with notable levels in hematopoietic cells and within the endoplasmic reticulum.
Biological function summary
TCPTP plays a role in the control of cell growth differentiation and immune response. It functions independently not as part of a larger complex. This enzyme acts as a negative regulator of signaling pathways by dephosphorylating proteins that drive these cellular processes. Its activity ensures a balance in cellular signaling preventing overactivation which could lead to uncontrolled cell proliferation or inappropriate immune responses.
Pathways
TCPTP holds significant function in the JAK-STAT and insulin signaling pathways. Within the JAK-STAT pathway TCPTP dephosphorylates members such as JAK1 and JAK3 helping modulate cytokine responses and immune regulation. In the insulin signaling pathway it influences the dephosphorylation of the insulin receptor thereby impacting insulin sensitivity. Such interactions demonstrate its involvement in key cellular processes necessary for immune function and metabolic regulation.
TCPTP has associations with autoimmune diseases such as Type 1 Diabetes and Crohn's Disease. Reduced activity or altered expression of TCPTP has been observed in these conditions suggesting its regulatory role in immune tolerance. Furthermore its connection with proteins like the cytokine IL-6 in autoimmune responses implicates TCPTP in the disease mechanisms where disrupted signaling can contribute to chronic inflammation and immune system dysfunction.